A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies	Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm	Not yet recruiting	Phase 1	2025-12-19		NCT07294300

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Qilu Pharmaceutical Co., Ltd.	126

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Shanghai Jiaotong University School of Medicine Ruijin Hospital	Shanghai	China	1

Clinical trials